Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F11%3A00367620" target="_blank" >RIV/67985823:_____/11:00367620 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1371/journal.pone.0027126" target="_blank" >http://dx.doi.org/10.1371/journal.pone.0027126</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0027126" target="_blank" >10.1371/journal.pone.0027126</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet

Popis výsledku v původním jazyce

We investigated whether pioglitazone (as well as rosiglitazone), a TZD-drug, could elicit the additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice were fed a high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietarytreatments (i) cHF+F, cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with rosiglitazone; (iii) cHF+F+ROSI; (iv) cHF+PIO, cHF with pioglitazone; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites, development obesity, glucose homeostasis, plasma lipid levels and gene expression were evaluated. Both TZDs preserved glucose homeostasis and normal plasma lipid levels while inducing adiponectin. The beneficial effects of TZDs were further augmented by the combination treatments. Our results reveal differential effects of rosiglitazone and pioglitazone and support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient?s therapy

Název v anglickém jazyce

Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet

Popis výsledku anglicky

We investigated whether pioglitazone (as well as rosiglitazone), a TZD-drug, could elicit the additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice were fed a high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietarytreatments (i) cHF+F, cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with rosiglitazone; (iii) cHF+F+ROSI; (iv) cHF+PIO, cHF with pioglitazone; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites, development obesity, glucose homeostasis, plasma lipid levels and gene expression were evaluated. Both TZDs preserved glucose homeostasis and normal plasma lipid levels while inducing adiponectin. The beneficial effects of TZDs were further augmented by the combination treatments. Our results reveal differential effects of rosiglitazone and pioglitazone and support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient?s therapy

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

<a href="/cs/project/NS10528" target="_blank" >NS10528: Aditivní účinky omega 3 polynenasycených mastných kyselin a pioglitazonu v léčbě diabetu 2. typu</a><br>

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PLoS ONE

ISSN

1932-6203

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

14

Strana od-do

"e27126"

Kód UT WoS článku

000297197000028

EID výsledku v databázi Scopus

—